Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study.

Ghosal S, Sinha B

Clinical diabetes and endocrinology9 May 2018Cited by 15 (Europe PMC)

PMID29760945PMCIDPMC5941332DOI10.1186/s40842-018-0061-8PepBankPUB-29760945

Summary

BackgroundTherapy for Type 2 diabetes (T2D) has been transformed by the introduction of newer agents like Glucagon like Peptide Receptor Agonists (GLP-1RA) and Sodium-glucose linked transporter inhibitors (SGLT2i). However with co-initiation of SGLT2i and GLP-1RA in the DURATION 8 trial an improvement in HbA1c was noted but the beneficial effect was not equal to the sum of its parts. In view of this we proceeded to test the hypothesis that sequential addition of GLP-1RA therapy to metformin and SGLT-2i may be more beneficial.MethodsA retrospective real world observational case note study conducted in two diabetes care centres in India analyzed the first 60 consecutive T2D patients who could afford this therapy and had not achieved their glycaemic target (HbA1c < 7%)on metformin and SGLT2i. All these patients were additionally treated with either Dulaglutide or Liraglutide and followed up for 13 weeks.ResultsAcross the entire 13-week study period, both liraglutide and dulaglutide proved to be an excellent add on to metformin and SGLT-2 inhibitor. There was significant reduction in HbA1c and body weight. Liraglutide had an additional significant impact on systolic blood pressure reduction in contrast to the dulaglutide arm. Comparatively, liraglutide and dulaglutide achieved similar metabolic control. However, a larger proportion of patients achieved HbA1c below 7.0% in the liraglutide arm (63.3%) compared to the dulaglutide arm (30%) and this difference was statistically significant.ConclusionIn this retrospective study in Indian type 2 diabetic patients poorly controlled with metformin and SGLT-2 inhibitor we found a meaningful impact of adding a GLP-1 RA on all metabolic parameters. There were additional advantages seen with liraglutide as far achieving target HbA1c of less than 7% and also on the quantum of weight loss and systolic blood pressure reduction.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanObservational studyEfficacy outcome
In Indian patients with T2D, dulaglutide addition was linked to lower HbA1c than baseline.
In plain wordsIn Indian patients with T2D, dulaglutide addition was linked to lower HbA1c than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 13 weeksAs given in this study (human).
Source sentences
Summary
There was significant reduction in HbA1c and body weight.
2 context sentences(design, population, supporting numbers)
Summary · context
Across the entire 13-week study period, both liraglutide and dulaglutide proved to be an excellent add on to metformin and SGLT-2 inhibitor.
Summary · context
A retrospective real world observational case note study conducted in two diabetes care centres in India analyzed the first 60 consecutive T2D patients who could afford this therapy and had not achieved their glycaemic target (HbA1c < 7%)on metformin and SGLT2i. All these patients were additionally treated with either Dulaglutide or Liraglutide and followed up for 13 weeks.
Show in the study text Report a problemFND-2976094501
02HumanObservational studyEfficacy outcome
In Indian patients with T2D, liraglutide addition was linked to lower HbA1c than baseline.
In plain wordsIn Indian patients with T2D, liraglutide addition was linked to lower HbA1c than baseline.
Peptide
Liraglutide
Outcome
DecreaseHbA1c
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 13 weeksAs given in this study (human).
Source sentences
Summary
There was significant reduction in HbA1c and body weight.
2 context sentences(design, population, supporting numbers)
Summary · context
Across the entire 13-week study period, both liraglutide and dulaglutide proved to be an excellent add on to metformin and SGLT-2 inhibitor.
Summary · context
A retrospective real world observational case note study conducted in two diabetes care centres in India analyzed the first 60 consecutive T2D patients who could afford this therapy and had not achieved their glycaemic target (HbA1c < 7%)on metformin and SGLT2i. All these patients were additionally treated with either Dulaglutide or Liraglutide and followed up for 13 weeks.
Show in the study text Report a problemFND-2976094502
03HumanObservational studyEfficacy outcome
In Indian patients with T2D, dulaglutide addition was linked to lower body weight than baseline.
In plain wordsIn Indian patients with T2D, dulaglutide addition was linked to lower body weight than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBody weight
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 13 weeksAs given in this study (human).
Source sentences
Summary
There was significant reduction in HbA1c and body weight.
2 context sentences(design, population, supporting numbers)
Summary · context
Across the entire 13-week study period, both liraglutide and dulaglutide proved to be an excellent add on to metformin and SGLT-2 inhibitor.
Summary · context
A retrospective real world observational case note study conducted in two diabetes care centres in India analyzed the first 60 consecutive T2D patients who could afford this therapy and had not achieved their glycaemic target (HbA1c < 7%)on metformin and SGLT2i. All these patients were additionally treated with either Dulaglutide or Liraglutide and followed up for 13 weeks.
Show in the study text Report a problemFND-2976094503
04HumanObservational studyEfficacy outcome
In Indian patients with T2D, liraglutide addition was linked to lower body weight than baseline.
In plain wordsIn Indian patients with T2D, liraglutide addition was linked to lower body weight than baseline.
Peptide
Liraglutide
Outcome
DecreaseBody weight
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 13 weeksAs given in this study (human).
Source sentences
Summary
There was significant reduction in HbA1c and body weight.
2 context sentences(design, population, supporting numbers)
Summary · context
Across the entire 13-week study period, both liraglutide and dulaglutide proved to be an excellent add on to metformin and SGLT-2 inhibitor.
Summary · context
A retrospective real world observational case note study conducted in two diabetes care centres in India analyzed the first 60 consecutive T2D patients who could afford this therapy and had not achieved their glycaemic target (HbA1c < 7%)on metformin and SGLT2i. All these patients were additionally treated with either Dulaglutide or Liraglutide and followed up for 13 weeks.
Show in the study text Report a problemFND-2976094504
05HumanObservational studyEfficacy outcome
In Indian patients with T2D, liraglutide was linked to additional systolic blood pressure reduction compared with dulaglutide.
In plain wordsIn Indian patients with T2D, liraglutide was linked to additional systolic blood pressure reduction compared with dulaglutide.
Peptide
Liraglutide
Outcome
DecreaseSystolic blood pressure
Study
n: not reported in source
Comparator
Dulaglutide arm
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 13 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide had an additional significant impact on systolic blood pressure reduction in contrast to the dulaglutide arm.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective real world observational case note study conducted in two diabetes care centres in India analyzed the first 60 consecutive T2D patients who could afford this therapy and had not achieved their glycaemic target (HbA1c < 7%)on metformin and SGLT2i. All these patients were additionally treated with either Dulaglutide or Liraglutide and followed up for 13 weeks.
Show in the study text Report a problemFND-2976094505
06HumanObservational studyEfficacy outcome
In Indian patients with T2D, dulaglutide did not show the significant systolic blood pressure reduction seen with liraglutide.
In plain wordsIn Indian patients with T2D, dulaglutide did not show the significant systolic blood pressure reduction seen with liraglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeSystolic blood pressure
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 13 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide had an additional significant impact on systolic blood pressure reduction in contrast to the dulaglutide arm.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective real world observational case note study conducted in two diabetes care centres in India analyzed the first 60 consecutive T2D patients who could afford this therapy and had not achieved their glycaemic target (HbA1c < 7%)on metformin and SGLT2i. All these patients were additionally treated with either Dulaglutide or Liraglutide and followed up for 13 weeks.
Show in the study text Report a problemFND-2976094506
07HumanObservational studyEfficacy outcome
In Indian patients with T2D, liraglutide and dulaglutide were linked to similar metabolic control.
In plain wordsIn Indian patients with T2D, liraglutide and dulaglutide were linked to similar metabolic control.
Peptide
Liraglutide
Outcome
No significant changeMetabolic control
Study
n: not reported in source
Comparator
Dulaglutide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 13 weeksAs given in this study (human).
Source sentences
Summary
Comparatively, liraglutide and dulaglutide achieved similar metabolic control.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective real world observational case note study conducted in two diabetes care centres in India analyzed the first 60 consecutive T2D patients who could afford this therapy and had not achieved their glycaemic target (HbA1c < 7%)on metformin and SGLT2i. All these patients were additionally treated with either Dulaglutide or Liraglutide and followed up for 13 weeks.
Show in the study text Report a problemFND-2976094507
08HumanObservational studyEfficacy outcome
In Indian patients with T2D, dulaglutide and liraglutide were linked to similar metabolic control.
In plain wordsIn Indian patients with T2D, dulaglutide and liraglutide were linked to similar metabolic control.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeMetabolic control
Study
n: not reported in source
Comparator
Liraglutide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 13 weeksAs given in this study (human).
Source sentences
Summary
Comparatively, liraglutide and dulaglutide achieved similar metabolic control.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective real world observational case note study conducted in two diabetes care centres in India analyzed the first 60 consecutive T2D patients who could afford this therapy and had not achieved their glycaemic target (HbA1c < 7%)on metformin and SGLT2i. All these patients were additionally treated with either Dulaglutide or Liraglutide and followed up for 13 weeks.
Show in the study text Report a problemFND-2976094508
09HumanObservational studyEfficacy outcome
In Indian patients with T2D, liraglutide was linked to more HbA1c target responders than dulaglutide.
In plain wordsIn Indian patients with T2D, liraglutide was linked to more HbA1c target responders than dulaglutide.
Peptide
Liraglutide
Outcome
IncreaseHbA1c below 7%
Study
n: not reported in source
Comparator
Dulaglutide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 13 weeksAs given in this study (human).
Measurements
Responders
63.3%
liraglutide
Responders
30%
dulaglutide
Source sentences
Summary
However, a larger proportion of patients achieved HbA1c below 7.0% in the liraglutide arm (63.3%) compared to the dulaglutide arm (30%) and this difference was statistically significant.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective real world observational case note study conducted in two diabetes care centres in India analyzed the first 60 consecutive T2D patients who could afford this therapy and had not achieved their glycaemic target (HbA1c < 7%)on metformin and SGLT2i. All these patients were additionally treated with either Dulaglutide or Liraglutide and followed up for 13 weeks.
Show in the study text Report a problemFND-2976094509
10HumanObservational studyEfficacy outcome
In Indian patients with T2D, dulaglutide was linked to fewer HbA1c target responders than liraglutide.
In plain wordsIn Indian patients with T2D, dulaglutide was linked to fewer HbA1c target responders than liraglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c below 7%
Study
n: not reported in source
Comparator
Liraglutide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 13 weeksAs given in this study (human).
Measurements
Responders
30%
dulaglutide
Responders
63.3%
liraglutide
Source sentences
Summary
However, a larger proportion of patients achieved HbA1c below 7.0% in the liraglutide arm (63.3%) compared to the dulaglutide arm (30%) and this difference was statistically significant.
1 context sentence(design, population, supporting numbers)
Summary · context
A retrospective real world observational case note study conducted in two diabetes care centres in India analyzed the first 60 consecutive T2D patients who could afford this therapy and had not achieved their glycaemic target (HbA1c < 7%)on metformin and SGLT2i. All these patients were additionally treated with either Dulaglutide or Liraglutide and followed up for 13 weeks.
Show in the study text Report a problemFND-2976094510

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 2
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study.

Summary

Results from this study10

Version history

Subjects

Publication types

Keywords